Table 9.
Sunitinib in papillary and chromophobe non-clear cell RCC.
| Number | Median PFS in months | Median OS in months | |
|---|---|---|---|
| pRCC | |||
| Choueiri et al. [2008] | 13* | 11.9* | NA |
| Shi et al. [2015] | 25 | 6 | 9 |
| Plimack et al. [2010] | 23 | 1.6 | NA |
| Molina et al. [2012a] | 8 | 5.6 | NA |
| Tannir et al. [2012] | 27 | 1.6 | NA |
| Ravaud et al. [2015] | 15 Type I 46 Type II |
Type I pRCC: 6.6 Type II pRCC: 5.5 |
NA |
| Tannir et al. [2015]
ESPN trial |
14 Sunitinib 13 Everolimus |
Sunitinib 5.7 Everolimus 4.1 |
Sunitinib 16.6 Everolimus 14.9 |
| Armstrong et al. [2016]
ASPEN-trial |
33 Sunitinib 37 Everolimus |
Sunitinib 8.1 Everolimus 5.5 |
NA |
| ChRCC | |||
| Choueiri et al. [2008] | 7* | 8.9* | NA |
| Tannir et al. [2012] | 5 | 12.7 | NA |
| Tannir et al. [2015]
ESPN trial |
6 Sunitinib 6 Everolimus |
Sunitinib 8.9 Everolimus NA |
Sunitinib 31.6 Everolimus 25.1 |
| Armstrong et al. [2016]
ASPEN-trial |
10 Sunitinib 6 Everolimus |
Sunitinib 5.5 Everolimus 11.4 |
NA |
ChRCC, chromophobe RCC; OS, overall survival; PFS, progression-free survival; pRCC, papillary RCC; NA, not available; RCC, renal cell carcinoma.
*
Only sunitinib treated patients.